Product Description
Tranexamic acid is a synthetic derivative of the amino acid lysine.Tranexamic acid (commonly marketed in tablet form as Lysteda and in IV form as Cyklokapron in the U.S. and as Transamin,Transcam in Asia, and Espercil in South America) is often prescribed for excessive bleeding.
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Fibrin is the basic framework for the formation of a blood clot in hemostasis.Tranexamic acid has roughly 8 times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Function and Application 1.Menstrual bleeding of Pure Tranexamic Acid
2.Orthopedic Surgery of Pure Tranexamic Acid
3.Trauma of Pure Tranexamic Acid
4.Dentistry of Pure Tranexamic Acid
5.In obstetrics, tranexamic acid is used after delivery to reduce bleeding, often with
6.In cardiac surgery, e.g. coronary artery bypass surgery, it is used to prevent excessive blood loss.
7.Whitening effect.Clinical studies for years have proved that tranexamic acid can dilute spot effectively and rapidly, which helps to demonstrate a perfect white and bright skin. The spot-removing effect of tranexamic acid is about 50 times over Vitamin C, and 10 times over AHA. The concentration limit of usage is 2%-3%, and in cosmetics the amount is around 0.5%
Product name | Tranexamic Acid |
Items | Standards | Results |
Appearance | White crystalline powder | Complies |
Solubility | Freely soluble in water and in glacial acetic acid,practically insoluble in alcohol | Complies |
Identification | Infrared absorption spectrophotometry(2.2.24);IR spectrum is in concordance with tranexamic acid CRS | Complies |
pH | 7.0~8.0 | 7.2 |
Related substances liquid chromatography(2.2.29) | ImpurityA≤0.1% | <0.1% |
ImpurityB≤0.2% | <0.2% |
Any other impurity≤0.1% | <0.1% |
All other impurity≤0.2% | <0.2% |
Heavy metals | ≤10ppm | <10ppm |
Chlorides | ≤140ppm | <140ppm |
Loss on dry | ≤0.5% | 0.38% |
Sulphated ash | ≤0.1% | <0.1% |
Assay | 99.0%~101.0% | 99.80% |
Conclusion | Conforms the standard |
What is Levodopa?
Levodopa is a naturally occurring dietary supplement and psychoactive drug found in certain kinds of herbs. The most common plant source of Levodopa marketed in this manner is Stizolobium cochinchin ensis (Lour) and Mucuna Pruriens. Some animals including humans make it via biosynthesis from the amino acid L-tyrosine. L-DOPA is synthesized from the amino acid L-tyrosine in the mammalian body and brain, it is the precursor to the neurotransmitters dopamine, and collectively known as catecholamines. L-DOPA can be manufactured and in its pure form is sold as a psychoactive drug with the INN levodopa. Aside from its natural and essential biological role, L-DOPA is also used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia. It is a prescription drug in the US.
Function and Application Used for the treatment of parkinsonian disorders and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Dietary supplement and psychoactive drug.
Product Name | Levodopa |
Reference | USP standard |
Test Items | Specifications | Results |
Appearance | White or almost white,crystalline powder | Almost white crystalline powder |
Identification | The infrared absorption spectrum is in accordance with the spectrum obtained with Levodopa RS. | Conform |
The retention time of the major peak from the Sample solution corresponds to that of the standard solution,as obtained in the test for Assay. | Conform |
Loss on drying | ≤0.5% | 0.1% |
Residue on ignition | ≤0.1% | <0.1% |
Specific rotation | -160° to-167° | -161° |
Related substances (HPLC) | USP impurity A≤0.1% | <RL(RL:0.03%) |
L-Tyrosine≤0.1% | <RL(RL:0.03%) |
USP impurity B≤0.5% | <LOD(LOD:0.004%) |
L-Veratrylglycine≤0.1% | <LOD(LOD:0.005%) |
Any individual unspecified impurity≤0.1% | <RL(RL:0.03%) |
Total impurities≤1.1% | <RL |
Assay (HPLC) | 98.0%~102.0% (calculated on dried basis) | 99.2% |
Residual solvents(GC) | Ethanol≤5000ppm | <LOD(LOD:75ppm) |
Conclusion | Complies with USP standard |
What is Febuxostat ?
Febuxostat is a xanthine oxidase inhibitor, clinically used to treat hyperuricemia (gout). It is a new and highly effective selective inhibitor of non-purine xanthine oxidase. Xanthine oxidase is the key enzyme to promote uric acid production. Febuxosutan can reduce the uric acid level in the blood of patients with hyperuricemia and gout. Clinical studies have shown that the drug is safe and effective. The drug is metabolized through the liver and does not rely on renal excretion. Doses of 40 mg or 80 mg once daily are not recommended for gout patients without hyperuricemia.
Function and Application 1.Febuxostat(TEI 6720;TMX 67 ) is selective xanthine oxidase inhibitor with Ki of 0.6 nM.IC50 value: 0.6 nM (Ki)
2.Febuxostat (INN; trade names Adenuric [EU], Febutaz [India] and Uloric [US]) is a urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and chronic gout.
3.Febuxostat reduces the production of uric acid in your body. Uric acid buildup can lead to gout or kidney stones.
4.Febuxostat is used to treat gout.
5.Febuxosta ,is a anti-gout Pharmaceutical Raw Materials. Product Name | Febuxostat |
Reference | USDMF |
Test Items | Specifications | Results |
Appearance | White to almost white crystalline powder. | White crystalline powder |
*Solubility | Freely soluble in dimethyl sulfoxide.soluble in aceton e, sparingly soluble in ethanol,and practically insoluble in water. | Conform |
Identification | 1) The IR spectrum is in accordance with that of Febuxostat reference standard. | Conform |
2) The retention time of the major peak in the chromatogram of the Test solution corresponds to that in the chromatogram of the Standard solution, as obtained in the Assay. | Conform |
3) *The XRPD spectrum of the sample is Form III according with that of standard, the diagnostic powder diffraction at unique values of 2Θ are: Form III 5.54±0.2, 5.66±0.2, 7.82±0.2, 11.48±0.2, 12.62±0.2, 16.74±0.2, 17.32±0.2, 18.04±0.2, 18.34±0.2, 20.40±0.2, 23.74±0.2, 25.76±0.2, 26.04±0.2. | - |
Loss on drying | ≤0.5% | <0.1% |
Sulfated ash | ≤0.1% | <0.1% |
Related substances (HPLC) | Impurity A≤0.15% | 0.03% |
Impurity B≤0.15% | <LOD(LOD:0.002%) |
Any other impurity≤0.10% | <LOD(LOD:0.001%) |
Total impurities ≤0.5% | 0.03% |
Assay (HPLC) | 98.0~102.0% (calculated on dried basis) | 100.4% |
Residual solvents (GC) | Ethanol≤5000ppm | <LOD(LOD:6ppm) |
Ethyl acetat e≤5000ppm | 374ppm |
Tetrahydrofura n≤720ppm | <LOD(LOD:7ppm) |
N,N-dimethylformamid e≤880ppm | <LOD(LOD:21ppm) |
Conclusion | Complies with USDMF standard |
Levetiracetam is an antiepileptic , which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.Levetiracetam has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication.It is also used in veterinary medicine for similar purposes. Based on low-quality evidence, levetiracetam is about as effective as phenytoin for prevention of early seizures
after traumatic brain injury. Function and Application Levetiracetam is an antiepileptic ,, which is mainly used for the combined treatment of partial seizures in adults
and children over 4 years old.
1) Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case
of partial seizures
2) Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome
3) It is also sometimes used to treat neuropathic pain
Name of product | LEVETIRACETAM |
Characters | White Or White crystals Powder |
Identification |
A:Specific optical rotation | -76°to -82° |
B:IR | The spectrum obtained from samples consists with that obtained from reference substance |
C:Enantiomeric purity | Meet the requirement (see tests) |
TESTS |
Appearance of solution | Clear and not more intensely coloured than BY6 |
Enantiomeric purity (impurity D ) | Not more than 0.8% |
Related substances |
Impurity A | Not more than 0.3% |
Unspecified impurity | Not more than 0.05% |
Sunof unspecified impurities | Not more than 0.1% |
Total impurities | Not more than 0.4% |
Impurity F | Not more than 0.1% |
Heavy metals | Not more than 10ppm |
Water | Not more than 0.5% |
Sulfated Ash | Not more than 0.1% |
Residual solvents |
Assay | Not more than 600ppm |
Ethyl acetat | Not more than 5000ppm |
Benzene | Not more than 2ppm |
Assay (on anhydrous basis ) | 98.0%-102.0% OF C8H4N2O2 |
What is Mirabegron?
Mirabegron is for the treatment of urgency, urinary frequency, and urinary urge urinary incontinence associated with overactive bladder (OAB). Mirabegron is synthesized by coupling 4-nitrophenethyl amine to (R)-2-hydroxy-2-phenylacetic acid. The resulting amide is reduced to an amine. The nitro group is then reduced and the resulting is coupled to 2-(2-aminothiazol-4-yl) acetic acid to give mirabegron. Mirabegron has an EC50 of 22 nM (intrinsic activity=0.8) for β3-AR with no detectable activity for β1- andβ2-AR (EC50>10,000 nM). In an anesthetized rat rhythmic bladder contraction model in which bladder contractions are induced by saline, mirabegron at 3 mg/kg iv decreased the frequency of rhythmic bladder contraction without suppressing contraction amplitude. These data suggest that the activation of β3-AR increases bladder capacity without influencing the frequency of bladder contraction.
Function and Application 1.Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM.
2.Uses for A potent bladder relaxant compound
3.Uses for Potent bladder relaxant and reagent for diabetes remedy.;Labeled Mirabegron, intended for use as an internal standard for the quantification of Mirabegron by GC- or LC-mass spectrometry. More Products
Company Profile
Our Research
![Pharmaceutical Raw Material Tranexamic Acid Febuxostat Irbesartan Niclosamide Levodopa Levetiracetam Mirabegron Fenbendazole Mebendazole Research Chemical](//image.made-in-china.com/226f3j00lNdRmBgGEWcU/Pharmaceutical-Raw-Material-Tranexamic-Acid-Febuxostat-Irbesartan-Niclosamide-Levodopa-Levetiracetam-Mirabegron-Fenbendazole-Mebendazole-Research-Chemical.webp)
Certifications&Exibition
![Pharmaceutical Raw Material Tranexamic Acid Febuxostat Irbesartan Niclosamide Levodopa Levetiracetam Mirabegron Fenbendazole Mebendazole Research Chemical](//image.made-in-china.com/226f3j00oNdUAlurEWqG/Pharmaceutical-Raw-Material-Tranexamic-Acid-Febuxostat-Irbesartan-Niclosamide-Levodopa-Levetiracetam-Mirabegron-Fenbendazole-Mebendazole-Research-Chemical.webp)
Packaging & Shipping
![Pharmaceutical Raw Material Tranexamic Acid Febuxostat Irbesartan Niclosamide Levodopa Levetiracetam Mirabegron Fenbendazole Mebendazole Research Chemical](//image.made-in-china.com/226f3j00oOmUdCuJwWkR/Pharmaceutical-Raw-Material-Tranexamic-Acid-Febuxostat-Irbesartan-Niclosamide-Levodopa-Levetiracetam-Mirabegron-Fenbendazole-Mebendazole-Research-Chemical.webp)
FAQ
Q1:Can you give me a discount price?A1:Sure, it depends on your quantity. |
Q2: What about the lead time? A2:Sample needs 3-5 days, mass production time needs 1-2 weeks for order quantity. |
Q3:How do you control the quality? A3:We will make samples before mass production, and after sample approved, we will begin bulk production. |
Q4:How do you ship the goods and how long does it take to arrive? A4:We usually ship by UPS, FedEx or TNT. It usually takes 3-5 days to arrive. Airline and sea shipping also optional. |
Q5:What is you terms of payment?A5:Our normal payment term is T/T 30% deposit after order signed and 70% before shippment. |
Q6:Is there cheap shipping cost to import to our country? A6:For small order, express will be best. And for bulk order, sea ship way is best but take much time. |